ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ANRO
GlobeNewswire News Room· 2025-08-27 19:15
NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto’s initial public offering conducted on or about February 2, 2024 (the “IPO”); and/or (ii) securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”), of the important September 19, 2025 lead plaintiff deadline. SO WHAT: If you purchased Alto securities you ...
Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.
Prnewswire· 2025-08-27 19:07
Core Viewpoint - Novavax's Nuvaxovid™ has been approved by the U.S. FDA for the 2025-2026 vaccination season, making it the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for high-risk adults aged 12 to 64 and seniors aged 65 and older [1][4]. Group 1: Vaccine Approval and Target Population - The FDA approval allows Nuvaxovid to be administered to adults 65 years and older, or individuals aged 12 to 64 with at least one underlying condition that increases their risk for severe COVID-19 outcomes [1][4]. - Novavax plans to collaborate with Sanofi to ensure access to the vaccine for eligible individuals this fall [2]. Group 2: Clinical Data and Efficacy - Clinical and preclinical data indicate that Nuvaxovid is safe and effective against COVID-19, particularly the JN.1 strain, which is responsible for the majority of global infections as of July 2025 [3]. - The vaccine induces immunity across various circulating strains within the JN.1 lineage, including NB.1.8.1, LP.8.1, XFG, XFC, LF.7, and XEC [3]. Group 3: Commercialization and Royalties - Sanofi is leading the commercialization efforts for Nuvaxovid, while Novavax is set to receive ongoing tiered royalties from the vaccine sales [3]. Group 4: Vaccine Composition and Technology - Nuvaxovid is a protein-based vaccine that targets the JN.1 variant, utilizing Novavax's recombinant nanoparticle technology to create copies of the SARS-CoV-2 spike protein [8][9]. - The Matrix-M® adjuvant enhances the immune response and allows for a lower dose of the antigen while maintaining effectiveness [10]. Group 5: Company Overview - Novavax, Inc. focuses on addressing significant health challenges through its expertise in vaccines and technology platforms, including protein-based nanoparticles and the Matrix-M adjuvant [11]. - The company's growth strategy includes optimizing existing partnerships, expanding access to its technology, and pursuing research and development innovations [11].
Circle and Paxos Team to Help Verify Crypto Payments
PYMNTS.com· 2025-08-27 19:03
Core Insights - Circle and Paxos Trust have developed a method to assist companies in verifying their digital asset holdings, utilizing cryptography and blockchain technology [2][3] - The partnership signifies the maturation of the digital asset industry in response to new global regulatory requirements, such as the GENIUS Act in the United States, which governs stablecoins [4] Group 1: Technology and Verification - The collaboration with Bluprynt allows for issuer verification of stablecoins, enabling tracing of tokens back to verified issuers [2] - The technology provides upfront provenance, reducing complexity and enhancing transparency for regulators and investors, which can mitigate risks from counterfeit tokens and impersonation attacks [3] Group 2: Regulatory Environment - The GENIUS Act, passed in July, is the first legislation in the U.S. specifically addressing stablecoins, indicating a shift towards regulatory oversight in the digital asset space [4] - Blockchain analysis firms have highlighted distinct security risks associated with stablecoins, including impersonation and fake tokens [5] Group 3: Integration Challenges - Circle's partnership with Finastra aims to facilitate the integration of stablecoin settlements into cross-border payment flows, utilizing Finastra's payment hub solutions [6] - The integration of stablecoins into the financial system faces challenges due to the lack of universality, as different versions of the same stablecoin can behave differently across various blockchain networks [7][8]
ROSEN, LEADING INVESTOR COUNSEL, Encourages PubMatic, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PUBM
GlobeNewswire News Room· 2025-08-27 19:00
Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased PubMatic, Inc. securities between February 27, 2025, and August 11, 2025, due to alleged misleading statements made by the company regarding its business operations and revenue impacts from a significant demand side platform buyer [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that PubMatic made false and misleading statements and failed to disclose critical information about a top demand side platform buyer shifting clients to a new platform, resulting in reduced ad spend and revenue for PubMatic [5]. - Investors who purchased PubMatic securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Investors interested in joining the class action can do so by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by October 20, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4].
Quest PharmaTech Announces Results from AGM
Globenewswire· 2025-08-27 18:57
Core Points - Quest PharmaTech Inc. held its annual general meeting on August 25, 2025, where four directors were re-elected to the Board of Directors [1] - The company reported that approximately 50,288,000 shares were voted, representing about 29.7% of the eligible shares [2] - Quest granted 1,900,000 stock options to Directors and Officers at an exercise price of $0.05 per share, expiring in 10 years, pending TSX Venture Exchange approval [3] Company Overview - Quest PharmaTech Inc. is a Canadian biopharmaceutical company focused on developing products to enhance quality of life through proprietary technologies and investee companies [4] - The company is developing MAb-AR9.6, a theranostic agent targeting MUC16 for cancer, which is currently in late preclinical stage development [4] - Quest holds a 42.5% interest in OncoQuest Inc., which sold its immunotherapy technology assets in April 2020, and a 23% interest in OncoVent, a joint venture in China focused on antibody-based immunotherapeutic products for cancer [4]
MA Expands Tie-Up With Circle to Boost Stablecoin Settlements in EEMEA
ZACKS· 2025-08-27 18:56
Core Insights - Mastercard has strengthened its partnership with Circle to introduce USDC and EURC settlements for acquirers in the EEMEA region, with Arab Financial Services and Eazy Financial Services being the first to benefit from this initiative [1][10] - The expanded partnership allows acquiring institutions to settle transactions in USDC or EURC, facilitating faster and more cost-efficient digital trade across emerging markets [2][4] - This initiative aligns with Mastercard's strategy to promote stablecoin adoption, enhance payment capabilities, and expand its presence in the crypto ecosystem [3][4] Company Developments - Mastercard supports various regulated stablecoins, including USDC, USDG, FIUSD, and PYUSD, while also advancing cross-border remittances and B2B payments through its platforms [4] - The collaboration with Circle is expected to increase the usage of Mastercard-branded cards and boost net revenues derived from its payment network, which saw a 17% year-over-year increase in total net revenues in Q2 2025 [5] Competitive Landscape - Competitors such as PayPal and Visa are also expanding their presence in the crypto space, with PayPal allowing users to buy and sell cryptocurrencies and Visa supporting crypto-linked card programs [6][7][8] - PayPal's net revenues rose 5% year-over-year in Q2 2025, while Visa's net revenues advanced 14% year-over-year in Q3 fiscal 2025 [7][8] Financial Performance - Mastercard's shares have increased by 25.4% over the past year, outperforming the industry's growth of 20.8% [9] - The Zacks Consensus Estimate for Mastercard's 2025 earnings indicates an 11.7% rise from the previous year, with a projected revenue growth of 15.1% year-over-year [13] Valuation Metrics - Mastercard trades at a forward price-to-earnings ratio of 32.75, which is above the industry average of 22.24 [12]
Williams-Sonoma Q2 Results Prove Its Buy-and-Hold Quality
MarketBeat· 2025-08-27 18:52
Core Viewpoint - Williams-Sonoma demonstrates strong financial performance and resilience against consumer headwinds, supported by robust cash flow and aggressive capital returns, including dividends and share buybacks [1][2][4]. Financial Performance - The company reported net revenue of $1.84 billion, a 2.8% increase year-over-year, slightly exceeding consensus estimates, with comparable sales up 3.7% [5]. - Operating margin increased by 220 basis points compared to last year, reaching the high end of the long-term target range, driven by wider gross margins and declining SG&A expenses [8]. Capital Returns - Williams-Sonoma is recognized for its aggressive capital return strategy, including a dividend yield of approximately 1.3% and a double-digit CAGR in distribution growth [2][3]. - The company has been actively buying back shares, reducing the share count by an average of 4.7% per quarter, supported by a healthy balance sheet and cash flow [2][4]. Market Outlook - The company raised its revenue outlook, forecasting top-line growth between 0.5% and 3.5%, with no additional impact from tariffs anticipated [8][9]. - Analysts maintain a consensus price target of $189.65, with a potential high forecast of $230.00, indicating strong institutional support and a bullish sentiment trend [10][12]. Institutional Activity - Institutional ownership is approximately 99%, with a recent shift from selling in Q1 to robust buying in Q2, resulting in a buy ratio of nearly 4-to-1 [10][11]. - The number of Buy ratings is increasing while Sell ratings are declining, reflecting a positive shift in analyst sentiment [12].
Amazon: Wide Moat And Prime Monetization - Outsized Upside Potential Ahead
Seeking Alpha· 2025-08-27 18:50
Group 1 - The analyst expresses a beneficial long position in shares of AMZN, NVDA, and CRWV through stock ownership, options, or other derivatives [2] - The article is written by the analyst and reflects their own opinions without any compensation from the companies mentioned [2] - The analysis is intended for informational purposes and emphasizes the importance of conducting personal research before investing [3] Group 2 - Past performance of stocks is not indicative of future results, and no specific investment recommendations are provided [4] - The views expressed may not represent those of Seeking Alpha as a whole, highlighting the diversity of opinions among analysts [4] - Analysts contributing to Seeking Alpha may not be licensed or certified by any regulatory body, indicating a mix of professional and individual investors [4]
Preferred Stocks With Room To Run
Seeking Alpha· 2025-08-27 18:46
Group 1 - The article provides profiles of two professionals with extensive backgrounds in nuclear engineering and environmental engineering, highlighting their educational qualifications and career experiences [1] - The first individual has a 41-year career in nuclear engineering, focusing on nuclear facility construction and government contracting, along with a long-term investment history with the Vanguard Group [1] - The second individual has a 35-year career in commercial nuclear power engineering services and nuclear waste clean-up, emphasizing safety in their work [1]
Is the Options Market Predicting a Spike in TROW Stock?
ZACKS· 2025-08-27 18:46
Group 1 - The stock of T. Rowe Price Group, Inc. (TROW) is experiencing significant attention due to high implied volatility in the options market, particularly the Sept. 19, 2025 $140 Put option [1] - Implied volatility indicates the market's expectation of future price movement, suggesting that investors anticipate a significant change in T. Rowe Price Group's stock price [2] - T. Rowe Price Group holds a Zacks Rank 2 (Buy) in the Financial - Investment Management industry, which is in the top 28% of the Zacks Industry Rank [3] Group 2 - Over the past 60 days, five analysts have raised their earnings estimates for T. Rowe Price Group for the current quarter, increasing the Zacks Consensus Estimate from $2.26 to $2.40 per share [3] - The high implied volatility may indicate a developing trading opportunity, as options traders often seek to sell premium on options with elevated implied volatility [4]